Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PTGX

Protagonist Therapeutics Inc

155.10

Aug 14 • 3:59 PM ET +3.68 (2.43%)

155.10

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Large NASD

Peers: BMRN INCY IONS AXSM MDGL RYTM ALNY VKTX KROS NBIX

| Held by: IJR VTI IWM VB XBI VBK XSMO SPSM VXF IJT

Scroll to Statements

Index	RUT
Market Cap	10.04B
Enterprise Value	9.26B
Income	82.91M
Sales	281.99M
Book/sh	13.01
Cash/sh	12.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	132
IPO	Aug 11, 2016

P/E	149.55
Forward P/E	-
PEG	-
P/S	35.59
P/B	11.92
P/C	12.82
P/FCF	76.86
EV/EBITDA	154.69
EV/Sales	32.85
Quick Ratio	21.71
Current Ratio	21.71
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	1.04
EPS next Y	-0.45
EPS next Q	1.91
EPS this Y	323.58%
EPS next Y	-109.88%
EPS next 5Y	-
EPS past 3/5Y	7.63% -1.26%
Sales past 3/5Y	20.07% 9.96%
EPS Y/Y TTM	44.59%
Sales Y/Y TTM	34.81%
EPS Q/Q	518.89%
Sales Q/Q	3749.17%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	1.05% 0.68%

Insider Own	5.34%
Insider Trans	-10.36%
Inst Own	115.49%
Inst Trans	11.72%
ROA	10.34%
ROE	10.98%
ROIC	9.77%
Gross Margin	99.45%
Oper. Margin	20.69%
Profit Margin	29.40%
SMA20	10.21%
SMA50	20.34%
SMA200	53.88%
Trades

Shs Outstand	64.67M
Shs Float	61.25M
Short Float	12.32%
Short Ratio	11.11
Short Interest	7.54M
52W High	154.99 0.07%
52W Low	54.18 186.27%
Volatility	3.30% 4.12%
ATR (14)	5.62
RSI (14)	70.14
Beta	1.80
Rel Volume	0.63
Avg Volume	679.02K
Volume	426,260

Perf Week	6.33%
Perf Month	17.48%
Perf Quarter	46.94%
Perf Half Y	89.31%
Perf YTD	77.58%
Perf Year	182.05%
Perf 3Y	714.17%
Perf 5Y	225.23%
Perf 10Y	1240.54%
Recom	1.07
Target Price	165.86
Prev Close	151.42
Price	155.10
Change %	2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-26	Upgrade	Goldman	Neutral → Buy	$186
May-21-26	Initiated	Wolfe Research	Outperform	$135
Sep-17-25	Initiated	Barclays	Overweight	$72
Sep-12-25	Initiated	Leerink Partners	Outperform	$73
Jun-17-25	Initiated	Citigroup	Buy	$72
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight

Show Previous Ratings

Aug-12-26 05:11AM	Silence cashes in on differentiated data; UK reaffirms support for childhood vaccines (BioPharma Dive)
Aug-05-26 04:25PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press) +6.45%
04:05PM	Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-04-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Jul-16-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE) +6.73%
04:05PM	Loading…
Jul-01-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE) +5.15%
Jun-16-26 04:00PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Jun-01-26 07:05AM	Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress (ACCESSWIRE)
May-28-26 07:05AM	Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 (ACCESSWIRE)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-06-26 03:11AM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press)
May-05-26 04:05PM	Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-28-26 09:05AM	Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration (ACCESSWIRE)
Apr-16-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Apr-14-26 06:55AM	J&J raises guidance for 2026 on strong start to the year (MarketWatch) +7.33%
10:05AM	Loading…
Mar-28-26 10:05AM	Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting (ACCESSWIRE)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com)
Mar-18-26 08:05AM	Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis (ACCESSWIRE)
Mar-02-26 02:00AM	Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Business Wire)
Feb-25-26 06:15PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
05:15PM	CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-24-26 07:30AM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 (ACCESSWIRE)
Feb-11-26 03:13PM	H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy (Insider Monkey)
Jan-07-26 07:30AM	Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 (ACCESSWIRE)
Jan-06-26 04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 04:21PM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
03:45AM	Loading…
Nov-27-25 03:45AM	Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice (ACCESSWIRE)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:05PM	Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting (ACCESSWIRE)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 07:35AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences (ACCESSWIRE)
Oct-18-25 12:04PM	Johnson & Johnson's M&A Strategy Is the Real Story for Investors (MarketBeat)
Oct-13-25 02:50PM	Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal (Zacks) -9.00%
06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
Oct-10-25 07:07PM	Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today (Motley Fool) +29.77%
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
01:38PM	RTW Investments' Rod Wong: Expect more deals in biotech space (CNBC TV)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
10:23AM	Stock Market Today: Market Tumbles After Trump Threatens "Massive Increase" on China Tariffs (TheStreet)
Oct-07-25 08:10AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill (ACCESSWIRE)
Sep-17-25 11:45AM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
08:00AM	Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress (ACCESSWIRE)
Sep-15-25 10:45AM	Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 (ACCESSWIRE)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-11-25 08:00AM	Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency (ACCESSWIRE)
Aug-26-25 04:05PM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 (ACCESSWIRE) +7.79%
Aug-25-25 07:00AM	Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera (ACCESSWIRE)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:24PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Jul-21-25 08:05AM	Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis (ACCESSWIRE)
Jun-30-25 04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily) -9.16%
04:05PM	Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity (ACCESSWIRE)
Jun-26-25 07:05AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate (ACCESSWIRE)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-23-25 01:17PM	Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains? (Zacks)
09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
Jun-09-25 10:00AM	For Patients With Rare Blood Cancer, New Drug Offers Relief (The Wall Street Journal)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 09:29AM	Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome (Insider Monkey)
May-21-25 07:05AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 (ACCESSWIRE)
May-12-25 08:11AM	J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study (Zacks) +5.35%
May-09-25 10:27AM	Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
08:05AM	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting (ACCESSWIRE)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.13%
04:05PM	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-23-25 10:35AM	Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 (ACCESSWIRE)
Apr-10-25 08:10AM	Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill (ACCESSWIRE)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)
Mar-08-25 09:15AM	Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis (ACCESSWIRE)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

CEODr. Dinesh V. Patel Ph.D.

Executive VP & CFOMr. Asif Ali

M.D.Dr. Arturo M. Molina FACP

EVP & Chief Technical OfficerMr. Venkat Thalladi Ph.D.

Executive VPDr. Newman Yeilding M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DINESH V PH D	President and CEO	Aug 10 '26	Option Exercise	21.58	65,761	1,419,122	589,239	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 11 '26	Option Exercise	21.58	34,239	738,878	557,717	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 10 '26	Sale	149.11	65,761	9,805,623	523,478	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 11 '26	Sale	148.52	34,239	5,085,176	523,478	Aug 12 06:43 PM
Dinesh Patel	CEO	Aug 10 '26	Proposed Sale	149.26	225,000	33,583,500		Aug 10 04:49 PM
Waddill William D.	Director	Jun 23 '26	Option Exercise	16.54	9,000	148,860	16,825	Jun 25 04:10 PM
Waddill William D.	Director	Jun 23 '26	Sale	117.94	9,000	1,061,460	7,825	Jun 25 04:10 PM
WILLIAM WADDILL	Director	Jun 23 '26	Proposed Sale	115.03	9,000	1,035,270		Jun 23 04:27 PM
Waddill William D.	Director	Jun 10 '26	Option Exercise	14.96	9,000	134,640	16,825	Jun 11 07:06 PM
Waddill William D.	Director	Jun 10 '26	Sale	107.68	9,000	969,120	7,825	Jun 11 07:06 PM
WILLIAM WADDILL	Director	Jun 10 '26	Proposed Sale	105.87	9,000	952,830		Jun 10 04:29 PM
Waddill William D.	Director	May 29 '26	Option Exercise	11.80	9,000	106,200	16,825	Jun 01 06:31 PM
Waddill William D.	Director	May 29 '26	Sale	99.64	9,000	896,760	7,825	Jun 01 06:31 PM
WILLIAM WADDILL	Director	May 29 '26	Proposed Sale	100.41	9,000	903,690		May 29 04:23 PM
PATEL DINESH V PH D	President and CEO	May 12 '26	Option Exercise	21.58	75,000	1,618,500	598,478	May 12 07:28 PM
PATEL DINESH V PH D	President and CEO	May 12 '26	Sale	100.12	75,000	7,509,000	523,478	May 12 07:28 PM
Dinesh Patel	CEO	May 12 '26	Proposed Sale	103.50	75,000	7,762,500		May 12 05:29 PM
Giraudo Bryan	Director	May 07 '26	Option Exercise	6.63	36,000	238,560	43,825	May 11 08:25 PM
Giraudo Bryan	Director	May 07 '26	Sale	100.14	36,000	3,605,040	27,825	May 11 08:25 PM
Giraudo Bryan	Director	May 07 '26	Sale	100.07	12,000	1,200,840	6,000	May 11 08:25 PM
Giraudo Bryan	Director	May 08 '26	Sale	100.00	6,000	600,000	0	May 11 08:25 PM
Giraudo Bryan	Director	May 08 '26	Sale	100.00	5,130	513,000	12,695	May 11 08:25 PM
BRYAN M & COURTNEY L GIRAUDO	Director	May 08 '26	Proposed Sale	100.00	11,130	1,113,000		May 08 04:23 PM
BRYAN GIRAUDO	Director	May 07 '26	Proposed Sale	100.14	36,000	3,604,968		May 07 05:21 PM
BRYAN M & COURTNEY L GIRAUDO	Director	May 07 '26	Proposed Sale	100.07	12,000	1,200,874		May 07 04:49 PM
Ali Asif	Chief Financial Officer	Apr 20 '26	Sale	105.47	1,750	184,572	59,003	Apr 21 04:58 PM
Asif Ali	Officer	Apr 20 '26	Proposed Sale	105.47	1,750	184,572		Apr 21 04:57 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 26 '26	Option Exercise	8.04	15,000	120,600	99,115	Mar 27 07:36 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 26 '26	Sale	104.79	15,000	1,571,850	84,115	Mar 27 07:36 PM
SELICK HAROLD E	Director	Mar 26 '26	Option Exercise	12.88	24,000	309,120	84,845	Mar 27 07:34 PM
SELICK HAROLD E	Director	Mar 26 '26	Sale	105.00	24,000	2,520,000	60,845	Mar 27 07:34 PM
Ali Asif	Chief Financial Officer	Mar 26 '26	Option Exercise	17.70	24,765	438,280	85,518	Mar 27 07:33 PM
Ali Asif	Chief Financial Officer	Mar 26 '26	Sale	104.24	24,765	2,581,504	60,753	Mar 27 07:33 PM
HAROLD SELICK	Director	Mar 26 '26	Proposed Sale	105.00	24,000	2,520,000		Mar 26 04:05 PM
ASIF ALI	Officer	Mar 26 '26	Proposed Sale	104.24	24,765	2,581,546		Mar 26 04:05 PM
ARTURO MOLINA	Officer	Mar 26 '26	Proposed Sale	104.79	15,000	1,571,919		Mar 26 04:01 PM
PATEL DINESH V PH D	President and CEO	Mar 25 '26	Option Exercise	8.58	54,641	468,820	579,579	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 24 '26	Option Exercise	8.58	59	506	524,997	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 25 '26	Sale	101.00	54,641	5,518,741	524,938	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 24 '26	Sale	101.00	59	5,959	524,938	Mar 25 07:23 PM
Dinesh Patel	CEO	Mar 24 '26	Proposed Sale	98.54	54,700	5,390,138		Mar 24 05:56 PM
Williams Lewis T	Director	Feb 17 '26	Option Exercise	10.84	18,000	195,120	25,825	Feb 18 06:12 PM
Williams Lewis T	Director	Feb 17 '26	Sale	82.42	18,000	1,483,560	7,825	Feb 18 06:12 PM
LEWIS T WILLIAMS	Director	Feb 17 '26	Proposed Sale	82.42	18,000	1,483,495		Feb 17 05:27 PM
Waddill William D.	Director	Feb 06 '26	Option Exercise	8.31	20,000	166,200	27,825	Feb 06 04:38 PM
Waddill William D.	Director	Feb 06 '26	Sale	83.68	20,000	1,673,600	7,825	Feb 06 04:38 PM
WILLIAM D WADDILL	Director	Feb 06 '26	Proposed Sale	83.68	20,000	1,673,672		Feb 06 04:04 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Option Exercise	14.12	24,890	351,528	588,710	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Option Exercise	21.58	4,068	87,787	578,573	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Option Exercise	4.21	19,315	81,316	593,820	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Sale	84.03	24,890	2,091,470	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Sale	84.59	19,315	1,633,856	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Sale	83.19	4,068	338,417	574,505	Jan 27 09:21 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Option Exercise	16.18	28,000	453,080	106,523	Jan 27 09:20 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Sale	83.13	46,203	3,841,037	60,320	Jan 27 09:20 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 23 '26	Sale	82.42	13,151	1,083,905	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Sale	82.28	5,000	411,400	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Sale	82.00	5,000	410,000	84,115	Jan 27 09:19 PM
ASIF ALI	Officer	Jan 27 '26	Proposed Sale	83.14	46,203	3,841,128		Jan 27 05:12 PM
ARTURO MOLINA	Officer	Jan 27 '26	Proposed Sale	82.00	5,000	410,000		Jan 27 04:01 PM
ARTURO MOLINA	Officer	Jan 26 '26	Proposed Sale	82.28	5,000	411,396		Jan 26 04:29 PM
ARTURO MOLINA	Officer	Jan 23 '26	Proposed Sale	83.42	13,151	1,097,116		Jan 23 04:32 PM
Dinesh Patel	CEO	Jan 23 '26	Proposed Sale	84.62	108,273	9,162,061		Jan 23 04:06 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 20 '26	Sale	82.48	9,514	784,715	97,266	Jan 21 05:17 PM
PATEL DINESH V PH D	President and CEO	Jan 20 '26	Sale	82.48	34,438	2,840,446	580,505	Jan 21 05:16 PM
Ali Asif	Chief Financial Officer	Jan 20 '26	Sale	82.48	8,588	708,338	78,077	Jan 21 05:15 PM
ARTURO MOLINA MD	Officer	Jan 20 '26	Proposed Sale	82.48	9,514	784,715		Jan 21 05:12 PM
DINESH V PATEL PH D	Officer, Director	Jan 20 '26	Proposed Sale	82.48	34,438	2,840,446		Jan 21 05:11 PM
Asif Ali	Officer	Jan 20 '26	Proposed Sale	82.48	8,588	708,338		Jan 21 05:10 PM
SELICK HAROLD E	Director	Jan 09 '26	Option Exercise	4.21	14,299	60,199	60,845	Jan 13 04:45 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 17 '25	Sale	84.77	2,712	229,896	81,180	Nov 19 04:01 PM
Waddill William D.	Director	Oct 10 '25	Option Exercise	6.98	12,000	83,760	17,130	Oct 14 04:01 PM
Waddill William D.	Director	Oct 10 '25	Sale	81.62	12,000	979,480	5,130	Oct 14 04:01 PM
WILLIAM WADDILL	Director	Oct 10 '25	Proposed Sale	67.04	12,000	804,480		Oct 10 04:18 PM
Waddill William D.	Director	Sep 22 '25	Sale	64.25	4,000	257,000	5,130	Sep 24 08:35 PM
WILLIAM WADDILL	Director	Sep 22 '25	Proposed Sale	62.20	4,000	248,800		Sep 22 04:27 PM
Waddill William D.	Director	Aug 27 '25	Sale	59.25	4,000	237,000	9,130	Aug 29 05:30 PM
WILLIAM WADDILL	Director	Aug 27 '25	Proposed Sale	56.99	4,000	227,960		Aug 27 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Upgrade your Finviz experience